Medtronic earns u.s. fda approval for the world's first adaptive deep brain stimulation system for people with parkinson's

New closed-loop system self-adjusts dbs therapy to individual brain activity  in real time; the largest commercial launch of brain-computer interface technology ever  galway, ireland , feb. 24, 2025 /prnewswire/ -- for the one million people diagnosed with parkinson's disease in the united states 1, medtronic plc (nyse:mdt), a global leader in healthcare technology, proudly announces u.s. food and drug administration (fda) approval of brainsense™ adaptive deep brain stimulation (adbs) and brainsense™ electrode identifier (ei). there is no cure for debilitating neurological conditions like parkinson's, however, deep brain stimulation (dbs) has been transforming the lives of people with parkinson's and other neurological disorders for more than 30 years.
MDT Ratings Summary
MDT Quant Ranking